ERBB2 and breast carcinoma: Clinical studies have investigated combinations such as Atezolizumab (a PD-L1 inhibitor) with Trastuzumab Emtansine (T-DM1), showing that this combination may improve progression-free survival in advanced HER2-positive breast cancer by enhancing immune-mediated tumor destruction (41).